Analysts Set Owens & Minor, Inc. (NYSE:OMI) Price Target at $20.00

Shares of Owens & Minor, Inc. (NYSE:OMI) have received an average rating of “Hold” from the eight ratings firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $20.00.

A number of research firms recently commented on OMI. Barclays lowered their price objective on shares of Owens & Minor from $23.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Monday, August 5th. Robert W. Baird dropped their price objective on Owens & Minor from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 16th. Citigroup raised Owens & Minor from a “neutral” rating to a “buy” rating and decreased their target price for the company from $24.00 to $19.00 in a research note on Friday, July 19th. StockNews.com lowered Owens & Minor from a “buy” rating to a “hold” rating in a report on Monday, August 26th. Finally, JPMorgan Chase & Co. cut their price target on shares of Owens & Minor from $22.00 to $18.00 and set an “underweight” rating for the company in a report on Wednesday, August 21st.

Owens & Minor Price Performance

Shares of OMI opened at $13.36 on Friday. Owens & Minor has a one year low of $12.36 and a one year high of $28.35. The stock’s fifty day moving average is $14.62 and its 200-day moving average is $16.33. The company has a debt-to-equity ratio of 2.17, a quick ratio of 0.51 and a current ratio of 1.09. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -23.86, a price-to-earnings-growth ratio of 0.41 and a beta of 0.41.

Owens & Minor (NYSE:OMI) last released its earnings results on Friday, August 2nd. The company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.33 by $0.03. The firm had revenue of $2.67 billion for the quarter, compared to analysts’ expectations of $2.65 billion. Owens & Minor had a negative net margin of 0.40% and a positive return on equity of 14.66%. Owens & Minor’s quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the company earned $0.18 EPS. Equities analysts anticipate that Owens & Minor will post 1.57 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Owens & Minor by 1.9% in the first quarter. Vanguard Group Inc. now owns 8,749,866 shares of the company’s stock worth $242,459,000 after buying an additional 162,182 shares during the period. Deerfield Management Company L.P. Series C boosted its position in Owens & Minor by 30.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 6,371,440 shares of the company’s stock worth $86,014,000 after acquiring an additional 1,493,852 shares during the period. Gabelli Funds LLC grew its stake in Owens & Minor by 25.9% during the 1st quarter. Gabelli Funds LLC now owns 170,000 shares of the company’s stock valued at $4,711,000 after acquiring an additional 35,000 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Owens & Minor by 16.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,246,600 shares of the company’s stock valued at $16,829,000 after purchasing an additional 176,250 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Owens & Minor by 1.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 4,534,204 shares of the company’s stock valued at $61,213,000 after purchasing an additional 76,599 shares during the period. 98.04% of the stock is currently owned by institutional investors and hedge funds.

About Owens & Minor

Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.